SIMLANDI is approved by the U.S. Food and Drug Administration (FDA) as the first high-concentration, citrate-free biosimilar to Humira with interchangeability exclusivity for the 40mg/0.4mL injection.

Find patient medical information for Amjevita(CF) Autoinjector subcutaneous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® Published Feb 23, 2024 8:15pm EST ...

References: US FDA approves high-concentration, citrate-free formulation of Cyltezo ® (adalimumab-adbm) injection, Boehringer Ingelheim’s interchangeable* biosimilar to Humira ®.News release ...

Yuflyma was first introduced in the U.S. market in July 2023 and is currently available as a 20mg, 40mg and 80mg solution for injection in prefilled syringes and as 40mg and 80mg in autoinjectors.

Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases such as rheumatoid ...

Biocon Biologics Ltd. grants Sandoz exclusive rights to promote, sell, and distribute Adalimumab BS in Japan. Viatris to provide transition support until Sandoz assumes responsibilities.

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...

Find patient medical information for Simlandi(CF) subcutaneous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 21, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced ...

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S.